Merck's Pipeline Gets Boost as CEO Sees Upside Potential
Merck & Co., Inc.'s (NYSE: MRK) CEO Rob Davis is optimistic about the company's pipeline, citing recent positive readouts and upcoming clinical catalysts. The pharmaceutical giant expects additional regulatory filings this year and sees its Animal Health business continuing to perform at 'best in industry levels.'
Davis stated that Merck's transformation is underway, driven by progress across product launches, clinical data readouts, business development, and the Animal Health segment. He noted that the company has been evaluating opportunities as a single pipeline, starting with scientific merit rather than a mandate to acquire an asset in a particular therapeutic area.
The CEO highlighted individualized neoantigen therapy, a program with Moderna in melanoma, which showed durable results in Phase 2 data. Merck is initially prioritizing tumor types with high tumor mutation burden or sensitivity to immuno-oncology treatments. Davis also mentioned the Terns acquisition and MK-2010, a PD-1-by-VEGF bispecific candidate, as opportunities not included in the company's $70 billion revenue estimate by 2035.
Merck is running 17 Phase 3 studies for sacituzumab tirumotecan, an antibody-drug conjugate targeting Trop-2, including 13 in tumor types where it believes the product could be first in class. The company is also studying the therapy in combinations with KEYTRUDA and MK-2010 in Phase 2 trials.